PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Reproductive Control Agents”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 541 records · Page 30Linked to original sources
PubMed1985

Increased euglobulin fibrinolytic potential in women on oral contraceptives low in oestrogen--levels of extrinsic and intrinsic plasminogen activators, prekallikrein, factor XII, and C1-inactivator.

Components of the fibrinolytic system were studied in samples of plasma from 15 normal, young women and from 11 women taking oral contraceptives containing 30 micrograms ethinyl oestradiol and 150 micrograms levo-norgestrel. Fibrinolytic activity of euglobulins precipitated at pH 5.9 was higher than normal in the hormone group, with significant fluctuations related to the cycle. Normal women showed only minor fluctuations. The concentration of C1-inactivator was lower in euglobulins of the hormone group. However, the difference in fibrinolytic activity was retained, when C1-inactivator was inactivated with sodium flufenamate. Fluctuations of the extrinsic (tissue-type) plasminogen activator (t-PA) activity parallelled those of the euglobulin activity. The intrinsic plasminogen activator activity (dextran sulphate precipitated euglobulin) was significantly increased in the hormone group and the cyclic pattern differed from that of the normal group. The increased activity was factor XII-dependent. Plasma prekallikrein did not differ. The factor XII level was increased in the hormone group but this could not explain the increased intrinsic fibrinolytic activity, suggesting an increase in the quantity of an additional factor XII-dependent proactivator.

Adult↗
PubMed1984

The relationship of estrogen and progesterone to breast disease.

The rising incidence of breast cancer, coupled with awareness of the effects of hormones on breast tissue, has resulted in fears that estrogen, progesterone or both incite or adversely affect benign and malignant breast disease. An intensive review of the hormone physiology of the breast and of the numerous studies on hormones and breast disease reveals that estrogen and especially oral contraceptives not only do not cause breast cancer but may have a slight protective effect. Also, the overwhelming evidence is that the risk of benign breast disease is substantially reduced in both current and prior users of oral contraceptives.

Breast Neoplasms↗
PubMedDate not supplied

Current contraceptive research.

No contraceptive panacea is near or likely. The most exciting prospect, man-made analogs of LHRH (a brain hormone) for both male and female use, could not be available before the late 1980s. Other potential methods in human trials face serious obstacles.

Abortifacient Agents↗
PubMed1982

Gallbladder disease in young women.

The records of 96 young women 25 years of age and less, who underwent cholecystectomy in the years 1977 to 1980 inclusive, were reviewed looking for correlations among obesity, parity, oral contraceptive usage and gallbladder disease. The main risk factor in this population was the presence, either past or present, of pregnancy. Oral contraceptive usage and obesity did not result in an increased risk of having gallbladder disease develop in this population. It is believed that this population is too young to demonstrate such an association. It was only when coupled with pregnancy that obesity or oral contraceptive usage resulted in an increased risk of having gallbladder disease develop.

Adult↗
PubMed1984

The epidemiology of ovarian cancer in Greece: a case-control study.

One hundred and fifty women with common malignant epithelial tumors of the ovary (cases) and 250 comparison women hospitalized for various orthopedic conditions were interviewed regarding demographic, reproductive, socio-economic and biomedical characteristics, including their use of coffee, tobacco, alcohol, drugs and exogenous estrogens. The data were analyzed with standard X2 procedures and by modelling relative risk (r) through multiple logistic regression. The main results are as follows: women with ovarian cancer had fewer liveborn children (one-tailed, P congruent to 0.13, for women with 4+ children, r = 0.6) and later menarche (P congruent to 0.02, for women with age at menarche 15+, r = 1.9) and menopause (P congruent to 0.07, for women with age at menopause 50+, r = 1.5); they were slightly taller and heavier (P congruent to 0.15 and 0.30 respectively); they belonged to smaller sibships (P congruent to 0.05); they reported more frequently than controls familial occurrence of ovarian, endometrial and breast cancer (P less than 0.05 in each instance); they were regular consumers of alcoholic beverages more frequently than controls, and the excess was both statistically significant (P congruent to 0.02) and dose-related; they were regular users of coffee slightly more frequently than controls (r = 1.2) but the excess was small and it was neither statistically significant nor dose-related (P congruent to 0.27); and they reported less frequently than controls the use of oral contraceptives (relative risk for users, 0.4; 95% confidence interval, 0.1-1.1).

Adult↗
PubMed1982

Breast cancer in relation to patterns of oral contraceptive use.

A total of 112 white females residents of King County, Washington, aged 35-54 years, who had received a first diagnosis of invasive breast cancer between July 1977 add August 1978, were investigated concerning prior use of oral contraceptives. Their responses were compared with those of a random sample of 469 demographically comparable women from the same population. Overall, oral contraceptive use in cases and controls was similar. However, use of oral contraceptives in preparous women was more common among cases than controls, with the estimated risk of breast cancer associated with such use being 2.2 times that of nonusers (90% confidence interval = 1.1-4.6). This relationship could be explained only in part by the effect of oral contraceptives in postponing or preventing childbirth. The association of breast cancer with use of oral contraceptives prior to ever giving birth has been observed in three studies, including this one, suggesting that the susceptibility of breast tissue to hormonal factors that influence the development of malignancy may be altered by having been exposed to the events of pregnancy.

Adult↗
PubMed1985

[Contraception in the hypertensive woman using a vaginal ring delivering estradiol and norgestrel].

A long term prospective study of contraceptive vaginal rings (CVR) that deliver estradiol and D-Norgestrel was conducted in 12 hypertensive women. Blood pressure was measured five times by an oscillometric automatic device during two control cycles, at the 1st, 2nd, 4th, 6th and 9th to 12th cycle of CVR use, and again after a one month recovery period. No significant change in blood pressure was noted during CVR usage and this method of contraception appeared safe in hypertensive women. Plasma renin substrate and plasma antithrombin III were non affected by the treatment. These observations are in marked contrast with the dramatic increase and decrease in these proteins that are respectively observed during oral estroprogestative contraception; and confirm the utility of a way of hormone administration that bypass the liver. The significant decrease in sex binding protein, HDL cholesterol, phospholipids and triglycerides that were observed under CVR treatment could be interpreted as reflecting the androgenic potency of D-Norgestrel.

Contraceptive Agents, Female↗